Loading…
Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment
Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly act...
Saved in:
| Published in: | Clinical and experimental immunology 2010-07, Vol.161 (1), p.134-141 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5875-e0780a711e74cbc72953050c16b4149b0e625faff3b4826398b2458abf95fea3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5875-e0780a711e74cbc72953050c16b4149b0e625faff3b4826398b2458abf95fea3 |
| container_end_page | 141 |
| container_issue | 1 |
| container_start_page | 134 |
| container_title | Clinical and experimental immunology |
| container_volume | 161 |
| creator | Barbai, V.H Ujhelyi, E Szlávik, J Vietorisz, I Varga, L Fey, E Füst, G Bánhegyi, D |
| description | Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4⁺ cell count ( |
| doi_str_mv | 10.1111/j.1365-2249.2010.04145.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2940158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746079420</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5875-e0780a711e74cbc72953050c16b4149b0e625faff3b4826398b2458abf95fea3</originalsourceid><addsrcrecordid>eNqNks2O0zAQxyMEYsvCK4AlhLiQYjt2Yh9AQtUCK63EgeVsOe64cUnsYifd7SPw1rjbUj4u4Is_5vefGc9MUSCC5ySv1-s5qWpeUsrknOL8ihlhfH57r5idDPeLGcZYlpJgdlY8Smmdr3Vd04fFGcUMC8HlrPi-6LRfQULOo7ED1MMW-oSCRSkMgLSZRig3nU6ANjGM4Pwd2k2D9sgNw-TDEqwzDrzZoa2LUypJJiyYEZZoo8dsGdMrZEPfhxvnV9k4Quxh-up8SdEYQY9DZh4XD6zuEzw57ufF9fuL68XH8urTh8vFu6vScNHwEnAjsG4IgYaZ1jRU8gpzbEjd5hrIFkNNudXWVi0TtK6kaCnjQrdWcgu6Oi_eHtxupnaApcmRo-7VJrpBx50K2qk_Ld51ahW2ikqGCRfZwcujgxi-TZBGNbhkoO-1hzAl1bAaN5JR_G-yqmQjcUMy-fwvch2m6HMZFOE5ey5owzIlDpSJIaUI9pQ1wWo_F2qt9u1X-_ar_Vyou7lQt1n69Pdfn4Q_ByEDL46ATkb3NmpvXPrFUVETxqrMvTlwN66H3X8noBYXl_tT1j876K0OSq9ijvHlcyYrTASTdc2qH7Si3qo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1545858274</pqid></control><display><type>article</type><title>Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment</title><source>PubMed Central</source><creator>Barbai, V.H ; Ujhelyi, E ; Szlávik, J ; Vietorisz, I ; Varga, L ; Fey, E ; Füst, G ; Bánhegyi, D</creator><creatorcontrib>Barbai, V.H ; Ujhelyi, E ; Szlávik, J ; Vietorisz, I ; Varga, L ; Fey, E ; Füst, G ; Bánhegyi, D</creatorcontrib><description>Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4⁺ cell count (<300/μl), have been treated with 3·6 M IU Proleukine® administered twice daily by subcutaneous injection over 5 days. C-reactive protein (CRP), d-dimer, C3, C9, C1-inh and alpha-2HS glycoprotein levels were measured immediately before IL-2 administration, as well as on day 5 and 2-3 weeks thereafter. After IL-2 administration, both mean d-dimer and CRP levels increased significantly (P < 0·001), but returned (P < 0·001) to baseline within the subsequent 2-3 weeks. Alpha-2HS glycoprotein decreased immediately after IL-2 administration. No significant differences were detected in the levels of C3, C9 and C1-inh. A significant, positive correlation (r = 0·5178, P = 0·0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL-2 administration, and changes in CD4 T cell counts measured 2-3 weeks before and after treatment, respectively. IL-2 administration induces rapid elevation of two major APPs (CRP, d-dimer). The positive correlation observed between the changes of CRP levels and CD4⁺ cell counts after IL-2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4⁺ cell count-increasing effect of the drug and/ or may be associated with serious side effects.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1111/j.1365-2249.2010.04145.x</identifier><identifier>PMID: 20408859</identifier><identifier>CODEN: CEXIAL</identifier><language>eng</language><publisher>Oxford, UK: Oxford, UK : Blackwell Publishing Ltd</publisher><subject>Acute phase substances ; acute-phase protein ; Acute-Phase Proteins - analysis ; Adult ; Alzheimer's disease ; Amyloid precursor protein ; Analytical, structural and metabolic biochemistry ; Anti-HIV Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Biological and medical sciences ; C-reactive protein ; CD4 antigen ; CD4 Lymphocyte Count ; Combined Modality Therapy ; Drug Administration Schedule ; Drugs ; Female ; Fibrin Fibrinogen Degradation Products - analysis ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Glycoproteins ; highly active antiretroviral therapy ; HIV infection ; HIV Infections - blood ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV-1 ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunodeficiency ; Immunologic Factors - therapeutic use ; Immunopathology ; Infectious diseases ; Injections, Subcutaneous ; Interleukin 2 ; Interleukin-2 - analogs & derivatives ; Interleukin-2 - therapeutic use ; Lymphocytes T ; Male ; Medical sciences ; Recombinant Proteins - therapeutic use ; Side effects ; Translational Studies ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Clinical and experimental immunology, 2010-07, Vol.161 (1), p.134-141</ispartof><rights>2010 British Society for Immunology</rights><rights>2015 INIST-CNRS</rights><rights>Journal Compilation © 2010 British Society for Immunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5875-e0780a711e74cbc72953050c16b4149b0e625faff3b4826398b2458abf95fea3</citedby><cites>FETCH-LOGICAL-c5875-e0780a711e74cbc72953050c16b4149b0e625faff3b4826398b2458abf95fea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940158/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940158/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22861443$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20408859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barbai, V.H</creatorcontrib><creatorcontrib>Ujhelyi, E</creatorcontrib><creatorcontrib>Szlávik, J</creatorcontrib><creatorcontrib>Vietorisz, I</creatorcontrib><creatorcontrib>Varga, L</creatorcontrib><creatorcontrib>Fey, E</creatorcontrib><creatorcontrib>Füst, G</creatorcontrib><creatorcontrib>Bánhegyi, D</creatorcontrib><title>Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4⁺ cell count (<300/μl), have been treated with 3·6 M IU Proleukine® administered twice daily by subcutaneous injection over 5 days. C-reactive protein (CRP), d-dimer, C3, C9, C1-inh and alpha-2HS glycoprotein levels were measured immediately before IL-2 administration, as well as on day 5 and 2-3 weeks thereafter. After IL-2 administration, both mean d-dimer and CRP levels increased significantly (P < 0·001), but returned (P < 0·001) to baseline within the subsequent 2-3 weeks. Alpha-2HS glycoprotein decreased immediately after IL-2 administration. No significant differences were detected in the levels of C3, C9 and C1-inh. A significant, positive correlation (r = 0·5178, P = 0·0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL-2 administration, and changes in CD4 T cell counts measured 2-3 weeks before and after treatment, respectively. IL-2 administration induces rapid elevation of two major APPs (CRP, d-dimer). The positive correlation observed between the changes of CRP levels and CD4⁺ cell counts after IL-2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4⁺ cell count-increasing effect of the drug and/ or may be associated with serious side effects.</description><subject>Acute phase substances</subject><subject>acute-phase protein</subject><subject>Acute-Phase Proteins - analysis</subject><subject>Adult</subject><subject>Alzheimer's disease</subject><subject>Amyloid precursor protein</subject><subject>Analytical, structural and metabolic biochemistry</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Biological and medical sciences</subject><subject>C-reactive protein</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count</subject><subject>Combined Modality Therapy</subject><subject>Drug Administration Schedule</subject><subject>Drugs</subject><subject>Female</subject><subject>Fibrin Fibrinogen Degradation Products - analysis</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glycoproteins</subject><subject>highly active antiretroviral therapy</subject><subject>HIV infection</subject><subject>HIV Infections - blood</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunodeficiency</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Injections, Subcutaneous</subject><subject>Interleukin 2</subject><subject>Interleukin-2 - analogs & derivatives</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Side effects</subject><subject>Translational Studies</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqNks2O0zAQxyMEYsvCK4AlhLiQYjt2Yh9AQtUCK63EgeVsOe64cUnsYifd7SPw1rjbUj4u4Is_5vefGc9MUSCC5ySv1-s5qWpeUsrknOL8ihlhfH57r5idDPeLGcZYlpJgdlY8Smmdr3Vd04fFGcUMC8HlrPi-6LRfQULOo7ED1MMW-oSCRSkMgLSZRig3nU6ANjGM4Pwd2k2D9sgNw-TDEqwzDrzZoa2LUypJJiyYEZZoo8dsGdMrZEPfhxvnV9k4Quxh-up8SdEYQY9DZh4XD6zuEzw57ufF9fuL68XH8urTh8vFu6vScNHwEnAjsG4IgYaZ1jRU8gpzbEjd5hrIFkNNudXWVi0TtK6kaCnjQrdWcgu6Oi_eHtxupnaApcmRo-7VJrpBx50K2qk_Ld51ahW2ikqGCRfZwcujgxi-TZBGNbhkoO-1hzAl1bAaN5JR_G-yqmQjcUMy-fwvch2m6HMZFOE5ey5owzIlDpSJIaUI9pQ1wWo_F2qt9u1X-_ar_Vyou7lQt1n69Pdfn4Q_ByEDL46ATkb3NmpvXPrFUVETxqrMvTlwN66H3X8noBYXl_tT1j876K0OSq9ijvHlcyYrTASTdc2qH7Si3qo</recordid><startdate>201007</startdate><enddate>201007</enddate><creator>Barbai, V.H</creator><creator>Ujhelyi, E</creator><creator>Szlávik, J</creator><creator>Vietorisz, I</creator><creator>Varga, L</creator><creator>Fey, E</creator><creator>Füst, G</creator><creator>Bánhegyi, D</creator><general>Oxford, UK : Blackwell Publishing Ltd</general><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Oxford University Press</general><general>Blackwell Science Inc</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201007</creationdate><title>Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment</title><author>Barbai, V.H ; Ujhelyi, E ; Szlávik, J ; Vietorisz, I ; Varga, L ; Fey, E ; Füst, G ; Bánhegyi, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5875-e0780a711e74cbc72953050c16b4149b0e625faff3b4826398b2458abf95fea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acute phase substances</topic><topic>acute-phase protein</topic><topic>Acute-Phase Proteins - analysis</topic><topic>Adult</topic><topic>Alzheimer's disease</topic><topic>Amyloid precursor protein</topic><topic>Analytical, structural and metabolic biochemistry</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Biological and medical sciences</topic><topic>C-reactive protein</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count</topic><topic>Combined Modality Therapy</topic><topic>Drug Administration Schedule</topic><topic>Drugs</topic><topic>Female</topic><topic>Fibrin Fibrinogen Degradation Products - analysis</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glycoproteins</topic><topic>highly active antiretroviral therapy</topic><topic>HIV infection</topic><topic>HIV Infections - blood</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunodeficiency</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Injections, Subcutaneous</topic><topic>Interleukin 2</topic><topic>Interleukin-2 - analogs & derivatives</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Side effects</topic><topic>Translational Studies</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barbai, V.H</creatorcontrib><creatorcontrib>Ujhelyi, E</creatorcontrib><creatorcontrib>Szlávik, J</creatorcontrib><creatorcontrib>Vietorisz, I</creatorcontrib><creatorcontrib>Varga, L</creatorcontrib><creatorcontrib>Fey, E</creatorcontrib><creatorcontrib>Füst, G</creatorcontrib><creatorcontrib>Bánhegyi, D</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barbai, V.H</au><au>Ujhelyi, E</au><au>Szlávik, J</au><au>Vietorisz, I</au><au>Varga, L</au><au>Fey, E</au><au>Füst, G</au><au>Bánhegyi, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>2010-07</date><risdate>2010</risdate><volume>161</volume><issue>1</issue><spage>134</spage><epage>141</epage><pages>134-141</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><coden>CEXIAL</coden><abstract>Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-1 infected patients is well documented and generally used, but there is limited information about the changes of acute-phase protein (APP) levels in response to this treatment. Fifteen patients undergoing highly active anti-retroviral therapy (HAART) treatment, with undetectable viral load, but low CD4⁺ cell count (<300/μl), have been treated with 3·6 M IU Proleukine® administered twice daily by subcutaneous injection over 5 days. C-reactive protein (CRP), d-dimer, C3, C9, C1-inh and alpha-2HS glycoprotein levels were measured immediately before IL-2 administration, as well as on day 5 and 2-3 weeks thereafter. After IL-2 administration, both mean d-dimer and CRP levels increased significantly (P < 0·001), but returned (P < 0·001) to baseline within the subsequent 2-3 weeks. Alpha-2HS glycoprotein decreased immediately after IL-2 administration. No significant differences were detected in the levels of C3, C9 and C1-inh. A significant, positive correlation (r = 0·5178, P = 0·0008) was ascertained between the changes of CRP level, measured immediately before as well as 5 days after IL-2 administration, and changes in CD4 T cell counts measured 2-3 weeks before and after treatment, respectively. IL-2 administration induces rapid elevation of two major APPs (CRP, d-dimer). The positive correlation observed between the changes of CRP levels and CD4⁺ cell counts after IL-2 administration may indicate that the abrupt, but transitory overproduction of CRP might contribute to the CD4⁺ cell count-increasing effect of the drug and/ or may be associated with serious side effects.</abstract><cop>Oxford, UK</cop><pub>Oxford, UK : Blackwell Publishing Ltd</pub><pmid>20408859</pmid><doi>10.1111/j.1365-2249.2010.04145.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9104 |
| ispartof | Clinical and experimental immunology, 2010-07, Vol.161 (1), p.134-141 |
| issn | 0009-9104 1365-2249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2940158 |
| source | PubMed Central |
| subjects | Acute phase substances acute-phase protein Acute-Phase Proteins - analysis Adult Alzheimer's disease Amyloid precursor protein Analytical, structural and metabolic biochemistry Anti-HIV Agents - therapeutic use Antiretroviral Therapy, Highly Active Biological and medical sciences C-reactive protein CD4 antigen CD4 Lymphocyte Count Combined Modality Therapy Drug Administration Schedule Drugs Female Fibrin Fibrinogen Degradation Products - analysis Follow-Up Studies Fundamental and applied biological sciences. Psychology Glycoproteins highly active antiretroviral therapy HIV infection HIV Infections - blood HIV Infections - drug therapy HIV Infections - immunology HIV-1 Human immunodeficiency virus Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunodeficiency Immunologic Factors - therapeutic use Immunopathology Infectious diseases Injections, Subcutaneous Interleukin 2 Interleukin-2 - analogs & derivatives Interleukin-2 - therapeutic use Lymphocytes T Male Medical sciences Recombinant Proteins - therapeutic use Side effects Translational Studies Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A55%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20the%20levels%20of%20some%20acute-phase%20proteins%20in%20human%20immunodeficiency%20virus-1%20infected%20patients,%20following%20interleukin-2%20treatment&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=Barbai,%20V.H&rft.date=2010-07&rft.volume=161&rft.issue=1&rft.spage=134&rft.epage=141&rft.pages=134-141&rft.issn=0009-9104&rft.eissn=1365-2249&rft.coden=CEXIAL&rft_id=info:doi/10.1111/j.1365-2249.2010.04145.x&rft_dat=%3Cproquest_pubme%3E746079420%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5875-e0780a711e74cbc72953050c16b4149b0e625faff3b4826398b2458abf95fea3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1545858274&rft_id=info:pmid/20408859&rfr_iscdi=true |